Montréal, Canada
Montréal, Canada

Time filter

Source Type

News Article | February 27, 2017
Site: www.eurekalert.org

(PRINCETON, N.J., Feb. 27, 2017) - Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance Immuno-Oncology (I-O) science and translational medicine to improve patient outcomes. Launched in 2012 by Bristol-Myers Squibb, the II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O, and has expanded from 10 to 15 sites including more than 250 investigators working on over 150 projects across 20 tumor types. The II-ON has generated cutting-edge I-O data that have informed the development of new I-O agents, yielded publications and produced some of the earliest findings on a variety of biomarkers and target identification and validation. "Bristol-Myers Squibb has long believed the future of cancer research is dependent on investments in science and partnerships. We formed the II-ON to facilitate innovation in I-O science and drug discovery by providing a streamlined framework for peer-to-peer collaboration among global cancer research leaders," said Nils Lonberg, Head of Oncology Biology Discovery at Bristol-Myers Squibb. "The significant discoveries generated by the II-ON over the past five years have not only informed our robust early I-O pipeline, but also serve to advance the entire field. We are proud to collaborate with Columbia University Medical Center and Peter Mac, and together with the entire II-ON will continue to lead pioneering research and heighten our collective understanding of the science behind I-O." Through the II-ON, Bristol-Myers Squibb is collaborating with leading cancer research institutions around the world to generate innovative I-O science, launch biology-driven trials and seek out cutting-edge technologies with the goal of translating research findings into clinical trials and, ultimately, clinical practice. "I-O research may be transforming the way we treat cancer," said Charles G. Drake, MD, PhD, Professor of Medicine at Columbia University Medical Center and Director of Genitourinary Oncology and Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center at New York-Presbyterian/Columbia. "The II-ON offers a tremendous opportunity to work smarter and faster along with our colleagues to address fundamental scientific questions in I-O." "We believe the collective knowledge and research power of the II-ON will generate groundbreaking findings in I-O with the potential to improve outcomes for people affected by cancer," said Professor Joe Trapani, Executive Director Cancer Research and Head of the Cancer Immunology Program at Peter MacCallum Cancer Centre, Melbourne, Australia. Building on the success of the II-ON, Bristol-Myers Squibb has invested in several other models of scientific collaboration with academic partners across the globe, including the Global Expert Centers Initiative (GECI) and the Immuno-Oncology Integrated Community Oncology Network (IO-ICON). "We believe a one-size-fits-all research approach does not facilitate innovation," said Lonberg. "Our tailored collaborations with academic centers expand our research capabilities and accelerate our collective ability to deliver potentially life-changing results for patients." The II-ON, formed in 2012, is a global peer-to-peer collaboration between Bristol-Myers Squibb and academia advancing the science of Immuno-Oncology (I-O) through a series of preclinical, translational and biology-focused research objectives. The research in the collaboration is focused on three fundamental scientific pillars: understanding the mechanisms of resistance to immunotherapy; identifying patient populations likely to benefit from immunotherapy; and exploring novel combination therapies that may enhance anti-tumor response through complementary mechanisms of action. The II-ON facilitates the translation of scientific research findings into drug discovery and development, with the goal of introducing new treatment options into clinical practice. In addition to Bristol-Myers Squibb, the II-ON currently comprises 15 leading cancer research institutions, including: Clinica Universidad Navarra, Dana-Farber Cancer Institute, The Earle A. Chiles Research Institute (Providence Health & Services), Institut Gustave Roussy, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale", Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center, Memorial Sloan Kettering Cancer Center, National Cancer Center Japan, The Netherlands Cancer Institute, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, University College London, The University of Chicago, West German Cancer Center/University Hospital Essen, and now Columbia University Medical Center and Peter MacCallum Cancer Centre. Bristol-Myers Squibb: At the Forefront of Immuno-Oncology Science & Innovation At Bristol-Myers Squibb, patients are at the center of everything we do. Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O) medicines that will raise survival expectations in hard-to-treat cancers and will change the way patients live with cancer. We are leading the scientific understanding of I-O through our extensive portfolio of investigational and approved agents - including the first combination of two I-O agents in metastatic melanoma - and our differentiated clinical development program, which is studying broad patient populations across more than 20 types of cancers with 12 clinical-stage molecules designed to target different immune system pathways. Our deep expertise and innovative clinical trial designs uniquely position us to advance the science of combinations across multiple tumors and potentially deliver the next wave of I-O combination regimens with a sense of urgency. We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and inform which patients will benefit most from I-O therapies. We understand making the promise of I-O a reality for the many patients who may benefit from these therapies requires not only innovation on our part, but also close collaboration with leading experts in the field. Our partnerships with academia, government, advocacy and biotech companies support our collective goal of providing new treatment options to advance the standards of clinical practice. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook. This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2016 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


WYNNEWOOD, PA, March 03, 2017-- Dr. Howard J. Eisen has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Inspired by a personal interest in the field, Dr. Eisen has dedicated his career to advancing cardiovascular medicine. His journey started at Cornell University and the University of Pennsylvania, where he earned a Bachelor of Arts in biology and an MD, respectively, and continued at the Hospital of the University of Pennsylvania, where he served as a medical intern and resident of medicine. Dr. Eisen did his Cardiovascular Medicine Fellowship at Washington University in St. Louis/Barnes Hospital. Dr. Eisen proceeded to acquire various academic roles for the University of Pennsylvania, Temple University, and Drexel University. He has served as the Thomas J. Vischer professor of medicine at Drexel's College of Medicine since 2004 and as a member of study section for the National Institutes of Health since 1999. Over the years, he has worked in the areas of cardiology, cardiovascular disorders, heart failures and transplants, and general clinical research.In order to keep abreast of changes in his field, Dr. Eisen affiliates himself with the American College of Cardiology, the American Society of Transplantation, the International Society of Heart and Lung Transplantation, and the American Federation of Clinical Research. He is also a diplomate through the American Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Cardiovascular Diseases. Dr. Eisen is Boarded by the ABIM in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure & Transplant Cardiology. Notably, he has been named a top doctor in Philadelphia Magazine and Castle & Connolly's Top Doctors in America every year since 1996, and in 2006, he was awarded the Alumni Service Award through the American Federation of Clinical Research. Dr. Eisen has also been featured in the 1st through 8th editions of Who's Who in Medicine and Healthcare, and five editions of Who's Who in Science and Engineering.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


News Article | February 17, 2017
Site: www.24-7pressrelease.com

CAMARILLO, CA, February 17, 2017 /24-7PressRelease/ -- Perla Hernandez Lastra has joined project management firm S.L. Leonard & Associates as a senior project manager. Prior to joining S.L. Leonard & Associates, Hernandez Lastra served as the project manager on the 115,000 square foot Marciano Art Foundation Museum adaptive re-use project in Los Angeles, with a construction value over $21 million. "Perla brings a wealth of building experience to S.L. Leonard & Associates," says Sean Leonard, founder and president. "She's fluent in Spanish, is a LEED Accredited Professional and has spent a good deal of time managing impressive projects. We're happy to have her join our team." In the short time Hernandez Lastra has been a senior project manager at SLL, she has worked on the Casa Pacifica Centers for Children & Families and the Primestor Development's Amara Regional Shopping Center - both in Camarillo. Casa Pacifica Centers for Children & Families is a $21 million project which consists of 46,000 square feet of state-of-the-art clinical, residential and administrative facilities, including two new cottages for housing youth with significant substance abuse issues, a training center and a renovation of the administrative building. The second phase will incorporate a therapeutic activities center and a new clinical building. Primestor Development's Amara Regional Shopping Center is a 44 acre project with 486,000 gross leasable square feet that will house many major national retailers and is scheduled to break ground this summer. During her tenure at a large national general contractor, one of Hernandez Lastra's major projects was the Great Wolf Lodge in Garden Grove, a 14 acre site containing a 132,000 square foot indoor water park, a 14,000 square foot wave pool, one outdoor and three indoor pools, and a nine-story Hotel Tower with 603 keys. The project also has a three-story lobby core building with 30,000 square feet of conference space and 18,000 square feet of retail and dining facilities, including five restaurants. The site houses a five-level design-build parking structure with 950 stalls. Hernandez Lastra is an instructor at UCLA Extension where she has been teaching the Construction Technology class since 2016. She is also a national trainer for SAP and Prolog. She taught Engineering Practices and Procedures, Field Operations, Technology, and Logistics at Turner's School of Construction Management for Minority/Woman/Disadvantaged Businesses from 2010 - 2016. She is a LEED Accredited Professional and is OSHA 30-hour certified, as well as CPR & First Aid Certified. Additionally, Hernandez Lastra is a member of the Society of Hispanic Professional Engineers, Engineers for a Sustainable World, Social Economic Environmental Design, and Cornell Society of Engineers. Hernandez Lastra holds a Bachelor of Science degree in Civil and Environmental Engineering from Cornell University and a Master of Engineering Management degree, also from Cornell University. S.L. Leonard & Associates is a comprehensive real estate development and project management firm based in Camarillo with a second office in Torrance. The firm has worked on numerous high-profile projects, including the Camarillo Public Library, the California Endowment's Headquarters and Conference Center, the City of Hope Helford Clinical Research Replacement Hospital, the mixed-use Working Artists Ventura development, the Museum of Ventura County expansion, Charles Drew University's Life Sciences and Nursing Education building and multiple affordable housing projects totaling more than 2,000 units. Prior to starting the firm, Leonard was senior vice president of project management for the Walt Disney Concert Hall. For more information, call (805) 445-4668 or visit http://www.slleonard.com.


News Article | February 22, 2017
Site: www.eurekalert.org

An international clinical trial conducted by the University of Liverpool has shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80% in individuals with obesity and prediabetes according to a study published today in The Lancet. This three-year SCALE obesity and prediabetes trial followed 2254 adults with prediabetes at 191 research sites in 27 countries worldwide. The aim was to evaluate whether liraglutide 3.0 mg can safely delay the onset of type 2 diabetes in participants with prediabetes. Prediabetes, also commonly referred to as borderline diabetes, is a metabolic condition and growing global problem that is closely tied to obesity. If undiagnosed or untreated, prediabetes can develop into type 2 diabetes; which whilst treatable is currently not fully reversible. In the UK 1 in 10 of the population have prediabetes. The associated health care cost to the economy is significant. These individuals are at risk of a range of conditions that can affect their overall health including type 2 diabetes and its complications as well as cardiovascular disease and cancer. Liraglutide promotes weight loss by interacting with the areas of the brain that control appetite and energy intake. The participants in the study, which was conducted at University Hospital Aintree, were randomly allocated to either liraglutide 3.0 mg or a placebo delivered by injection under the skin once daily for 160 weeks. They were also placed on a reduced calorie diet and advised to increase their physical activity. The study showed that three years of continuous treatment with once-daily liraglutide 3.0 mg, in combination with diet and increased physical activity, reduces the risk of developing type 2 diabetes by 80% and results in greater sustained weight loss compared to the placebo. Professor John Wilding, Professor of Medicine at the University of Liverpool and Honorary Consultant Physician is an obesity specialist was an investigator in the trial and an author of this study. Professor Wilding, said: "In this study, we wanted to see if this drug in combination with a reduced-calorie diet and lifestyle intervention could delay the onset of type 2 diabetes in a high-risk population with obesity and prediabetes. "On the basis of our findings, liraglutide 3.0 mg can provide us with a new therapeutic approach for patients with obesity and prediabetes to substantially reduce their risk of developing type 2 diabetes and its related complications. "As healthcare professionals, it is important that we can offer a treatment to our type 2 diabetes patients that we are confident will achieve results in the real-world that are consistent with the results of the clinical trial programme." The study is a continuation of work started by Professor Wilding in 1996 when he was working at the Hammersmith Hospital in London, and was part of the team that first showed that the hormone GLP-1, on which liraglutide is based, was involved in the control of food intake. Professor Wilding adds "It is very exciting to see a laboratory observation translated into a medicine that has the potential to help so many people, even though it has taken over 20 years." The full study, entitled '3 years' of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial', can be found here http://dx.doi.org/10.1016/S0140-6736(17)30069-7 once the embargo has lifted. According to http://www. there are 2.8 million people in the UK with type 2 diabetes. There are about 5 million at high risk (prediabetes); about 200000 of these will develop diabetes each year. For information about the NHS National Diabetes Prevention Programme please visit https:/ John Wilding leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool, UK. He trained in medicine in Southampton and at the Hammersmith Hospital, London where he also undertook three years laboratory-based research into the neurobiology of obesity and diabetes. He has worked at University Hospital Aintree, Liverpool since 1996 and as Professor of Medicine since 2005. He leads specialist services for severe obesity at University Hospital Aintree - designated a Centre for Obesity Management by the European Association for the Study of Obesity. He is a Council member of the Royal College of Physicians and chairs the UK National Clinical Research Network Metabolic and Endocrine Speciality Group. He has published over 250 research papers, chapters and review articles related to his clinical and laboratory research interests in the pathophysiology of obesity and type 2 diabetes and evaluation of new treatments. When not at work he likes to swim, bike and run and completed his first 'Iron distance' triathlon in 2015.


News Article | February 27, 2017
Site: www.prnewswire.co.uk

The report "(CTMS) Clinical Trial Management System Market Size By Component (Software, Hardware, Services), By Product (Enterprise Based, Site Based), By Delivery Mode (Web, Cloud, On Premise), By End Use (Pharmaceutical & Biopharmaceutical Companies, Clinical Research Organizations, Healthcare Providers), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Poland, Russia, China, India, Japan, South Korea, Taiwan, Brazil, Mexico, South Africa), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016 - 2024" by Global Market Insights, Inc. says CTMS Market size is poised to surpass USD 2 billion by 2024. Growing prevalence of chronic diseases, surge in clinical trials outsourcing, rising R&D cost and favorable government initiatives will drive global clinical trial management system market size. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1155 Improvements in regulatory framework for drug approvals and patent laws along with rapid economic development in emerging countries of India and China will expand clinical trial management system market size.  Quality trials at reduced cost continues to remain unique proposition for regional industry growth. Stringent regulatory guidelines to ensure drug safety & efficacy, extended approval time, difficulties in recruitment for trials and increasing number of clinical trial failures in phase II and phase III should hinder clinical trial management system market growth. Hardware component was valued at over USD 90 million in 2015, and is estimated to expand at 13.1% CAGR from 2016 to 2024. Pharmaceutical companies are outsourcing their requirement to specialized firms in other regions. This has resulted in increase in sales of hardware components used for clinical trial management system. Enterprise based accounted for over 70% of clinical trial management system market share in 2015 and is projected to grow at 13.8% CAGR from 2016 to 2024. It provides dedicated services with special in house capabilities for clinical trials management. Cloud delivery mode is projected to witness robust growth of over 15% from 2016 to 2024 and expected to reach over USD 350 million by 2024. In terms of revenue share, Web and On Premise together account for over 85% clinical trial management market share in 2015, growing at over 14% and 11.5% from 2016 to 2024 respectively. Pharmaceutical and biopharmaceutical companies are estimated to surpass USD 1.4 billion by 2024. As these organizations are continuously striving to develop potent novel drugs and therapeutics to use against diseases and disorders. China clinical trial management system market size is anticipated to generate over USD 270 million in terms of value by 2024. Increasing government policies to setup a research center and growing R&D investments in life sciences, pharmaceutical, and clinical research industries, along with combination of HIS with CTMS, additionally the increased clinical research outsourcing and increasing prevalence of diseases. Browse key industry insights spread across 105 pages with 92 data tables & 6 figures & charts from this 2017 report Clinical Trial Management System Market in detail along with the table of contents at: U.S. clinical trial management system market share was over 70% of regional industry revenue in 2015. The factors driving business growth include favorable regulatory environment, effective ADR monitoring and evaluation policies and improved government funding. Germany clinical trial management system market size held more than 15% industry share in 2015 and anticipated to exceed USD 180 million by 2024. Favorable clinical trial regulations should boost the industry growth over the forecast period. India clinical trial management system market size was around USD 50 million in 2015, expected to witness robust growth of more than 22% from 2016 to 2024 due to growing preference for conducting clinical trials associated with its low cost and good quality of trials. Latin America clinical trial management system market size is expected to surpass USD 110 million by 2024, owing to favorable government regulations and increased adoption of new medical technologies in the areas of clinical chemistry and biomedical research. Global clinical trial management system industry is highly fragmented and competitive in nature. Some of the notable industry players include MedNet Solutions, Oracle Corporation, Bio-Optronics, BioClinica, Medidata solutions, PAREXEL International Corporation, Merge Healthcare, DATATRAK International, and VEEVA Systems. Other prominent participants include eClinForce, Forte Research Systems, and DSG. Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1155 Clinical trial management system market research report includes in-depth coverage of the industry with estimates & forecast in terms of value and volume in USD million from 2012 to 2024 , for the following segments: The above information is provided on a regional and country basis for the following: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | February 15, 2017
Site: www.prweb.com

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a leader in providing fully integrated clinical research services to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials. Simultaneously enrolling in multiple clinical trials, or duplicate enrollment, has become a serious problem in the clinical research world. A growing number of research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse. This creates dangerous issues for the drug manufacturer, the research site, the data quality, and, most importantly, the volunteer. “We are pleased to have these two clinical research leaders join our network,” said Dr. Mitchell Efros, CEO of VCT. “Our system will allow both companies to take big steps forward in preventing duplicate enrollment and the risks associated.” VCT maintains a global clinical trial research subject database registry to counter attempts at duplicate enrollment in clinical trial research. The majority of phase I units and an increasingly large number of late phase sites in North America use Verified Clinical Trials, making VCT by far the largest North American clinical research subject database registry in both early and late phase clinical trials. “DCR is passionate about ensuring data quality and research subject safety,” said Amy Young, vice president and general manager of DCR. “Partnering with Prism and using the VCT system is the right thing to do for all our stakeholders.” Experts and leaders in the field of hepato-renal clinical trials, Prism and DCR join a vast network of research sites and pharmaceutical companies in their efforts to prevent duplicate enrollment and other important protocol violations in clinical trials. ”Prism is glad to be participating in this joint effort with our research neighbor, DCR,” said Jeff Cosgrove, president of Prism Research. “We’ve always been proactive in combating dual enrollment, but VCT gives us state-of-the-art technology and processes toward that end.” Located in close proximity to the Minneapolis and St. Paul metropolitan area, Prism and DCR specialize in early phase clinical research in healthy volunteer trials and many patient-based volunteer trials, including those in hepatic and renal insufficiency populations. About Prism Clinical Research Prism Clinical Research is a Twin Cities–based clinical research company committed to the advancement of improved medical knowledge and the community’s health. Since 2005, Prism has provided FDA-approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians, as well as other researchers across Minnesota. About DaVita Clinical Research DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, and Real World Healthcare Data are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit http://www.davitaclinicalresearch.com. About Verified Clinical Trials Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts duplicate enrollment in clinical trials and defines itself as the world’s leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials, and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and Pharmaceutical Sponsor that prove invaluable with regards to financial and legal issues and liabilities. Verified Clinical Trials prevents several other key protocol deviations. For more information, RSVP to or visit http://www.verifiedclinicaltrials.com.


News Article | February 20, 2017
Site: www.prweb.com

The 7th annual Great Debates & Updates in Hematologic Malignancies, an interactive, two-day debate-driven conference will highlight the most critical recent developments in hematologic malignancies, providing practical insights to community and academic oncologists. The conference will be held on April 7-8, 2017 at the New York Marriott Downtown in New York City, and more than 200 clinicians attend annually. This conference “addresses and summarizes the hottest topics in the field,” said John P. Leonard, MD, conference co-chair and Vice Chairman for Clinical Research of the Weill Cornell Department of Medicine. “Additionally, this meeting will highlight the key perspectives that clinicians and clinical research physicians working in hematologic malignancies need to consider in their daily activities.” With more than 100 clinical trials investigating hematologic malignancies currently underway community and academic oncologists will benefit greatly from the presentations covering advances in the field led by the more than 20 key opinion leaders from the world’s leading institutions who will serve as conference faculty. Both the debates and the selected presentations will give critical insight into how new advances and data can be incorporated into current practice. All talks integrate substantial audience interaction with faculty, allowing attendees to really engage with experts. “The field of hematology and hematological malignancies is rapidly evolving,” said David P. Steensma, MD, conference co-chair and Associate Professor of Medicine at Harvard Medical School. He adds, “This program includes a range of up-to-date, clinically-relevant topics in leukemia, lymphoma, myeloma, and non-neoplastic hematology and will cover all the relevant major topics discussed at the most recent ASH meeting in December. We have recruited faculty who are experienced clinicians and content experts in order to make the program as engaging and useful as possible.” Entering into its seventh year, Great Debates & Updates in Hematologic Malignancies is chaired by John P. Leonard, MD (Weill Cornell Medicine), Robert Z. Orlowski, MD, PhD (MD Anderson Cancer Center) and David P. Steensma, MD (Dana-Farber Cancer Institute.) Imedex will certify this Congress for up to 12.25 AMA PRA Category 1 Credits™. Successful completion of this CME activity will enable attendees to earn MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Conference registration is currently open and registration discounts are available when registering in advance. Visit http://www.GreatDebatesinHematologicMalignancies.com for additional information, including a full agenda listing with faculty presenters. About Imedex® Imedex is the industry leader in developing and delivering independent, accredited healthcare education. The Company’s programs specializing in hematology, oncology, and gastroenterology are provided through live events around the world as well as through effective online educational opportunities for on-the-go healthcare providers. Imedex’s high-quality scientific programming translates the latest research into clinically relevant information. Our activities facilitate the needs of time-constrained healthcare professionals who are inundated by information through exceptional organization and outstanding educational value — all with a proven and sustained impact on patient care. Imedex provides over 50,000 E-learning experiences annually and its live conferences have welcomed more than 100,000 attendees since 2001. The Company has a global footprint and operates in the United States, Europe, and Asia. At Imedex, we believe education is the best medicine®. For more information on Imedex and upcoming conferences, visit us online at http://www.imedex.com, on our E-learning Center at http://elc.imedex.com, or via email at registration(at)imedex(dot).com. Great Debates & Updates in GI Malignancies March 24-25, 2017 | New York, New York Wyndham New Yorker Hotel http://www.greatdebatesingimalignancies.com


News Article | February 26, 2017
Site: www.prweb.com

Occupational pesticide exposure is linked to an increased risk of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. Previous studies have provided evidence of a link between pesticides and incidence of sporadic PD through occupational exposure. This latest study, led by Caroline Tanner et al., investigated the role of pesticides on penetrance in LRRK2-associated PD, specifically in carriers with the G2019S mutation. The researchers identified symptomatic and asymptomatic PD subjects with the G2019S mutation who participated in an international LRRK2 study and provided information on occupational pesticide exposure. Findings were primarily observed in men, as few women were exposed to pesticides. Among PD symptomatic men, 20% of enrolled subjects were exposed to any type of pesticide compared to 4.7% of asymptomatic PD men. Furthermore, of the sample population, an increased hazard of PD was associated with occupational fungicide exposure, with 7.8% of symptomatic men compared to 0% of asymptomatic men. Mark Stacy, Professor of Neurology and Vice Dean for Clinical Research at Duke University School of Medicine, states, “This report offers an avenue of investigation to assess the long-standing hypothesis of an internal (genetic) risk requires an external (environmental) trigger to produce the syndrome. While there were no differences between women (who overall reported less occupational pesticide exposure than men), occupational fungicide use is definitively and herbicide or insecticide use is possibly associated with increased penetrance of PD in G2019S carriers in men.” Stacy adds, “Taken together, the advance in understanding of the genetic variations in our population, coupled with improved assessment of toxin exposure may allow us to identify a potential compound to modify the risk and rate of progression of PD.” About the 1st Pan American Parkinson’s and Movement Disorders Congress: Meeting attendees gather to learn about the latest research findings and relevant issues in the field of Movement Disorders specific to North, Central and South America. Over 400 physicians and medical professionals will be able to view over 150 scientific abstracts submitted by clinicians from the Pan American region and throughout the world. About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.


News Article | February 15, 2017
Site: globenewswire.com

The industry analysis report “Protein A Resins Market Size By Application (Immunoprecipitation, Antibody Purification), By Product (Natural protein A, Recombinant Protein A), By Matrix (Agarose, Glass/Silica Gel, Organic Polymer), By End Use (Biopharmaceutical, Clinical Research, Academic Research, CRO), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, Russia, Poland, Japan, China, India, Australia, Argentina, Brazil, Mexico, South Africa, UAE, Saudi Arabia, Qatar, Kuwait, Egypt), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” by Global Market Insights, Inc. says Protein A Resin Market size is slated to surpass USD 900 million by 2024. Protein A resins are crucial and are broadly used as purification and separation materials owing to high resolution, across the biopharmaceutical industry. They exploit the chemical and physical variances among biomolecules for separation of antibodies by immunoprecipitation and antibody purification. Growing diagnostic and therapeutic applications of monoclonal antibodies will be the major driver for protein A resins market size. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1146 High selectivity and improved antibody yield coupled with ease of operation in large and small scale antibody purification and immunoprecipitation will further drive the protein A resins market growth. Chromatography with these has several advantages as a separation method, over conventional techniques like solvent extraction, crystallization, and distillation. For instance, it can separate all the components of a multicomponent biochemical mixture without demanding a detailed foreknowledge of the number, identity, or relative quantities of the materials present in the mixture. U.S.  market growth will continue to dominate other regions due to presence of well-established infrastructure for clinical trials.  Recombinant protein A resins market will grow at significant CAGR of around 8% during the forecast period owing to the wealth of techniques and products used for their expression and purification. Contract research organizations (CROs) provide modified solutions for monoclonal antibody and recombinant protein production from mammalian cell culture. The segment accounted for second highest revenue share of around 15%. CROs also offer large-scale protein production and virus production, making it suitable for pharmaceutical and biotechnology companies as well as academic institutions to outsource processes. Browse key industry insights spread across 127 pages with 123 market data tables & around 8 figures & charts from this 2017 report Protein A Resins Market in detail along with the table of contents at: In 2015, Spain protein A resins market size was over USD 25 million, increasing investments by public and private companies in the development of biosimilars and increasing demand for biosimilar products are the significant factors driving the market for monoclonal antibodies and eventually Spain market growth. Asia Pacific protein A resins market will grow at highest CAGR of over 8.5%, favorable government policies, dynamic infrastructure development will attract international companies to set-up manufacturing plants in the region and availability of skilled professionals at affordable costs. The region has emerged as a preferred destination for contract research organizations and various biopharmaceutical companies to establish business. Japan protein A resins market accounted for over 40% share, as its healthcare infrastructure is experiencing noteworthy transformation. The government is strategically planning a regulatory system in which public and private companies will contribute to develop novel biosimilar products. India antibody purification market has witnessed notable growth in recent years, which could continue in the vicinity of 10%, with factors such as increasing research into the development monoclonal antibodies, driving protein A resins market growth. Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1146 Protein A resins market research report includes in-depth coverage of the industry  with estimates & forecast in terms of revenue in USD million from 2012 to 2024 , for the following segments: The above information is provided on a regional and country basis for the following : Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Loading Clinical Research collaborators
Loading Clinical Research collaborators